Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 883, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.ejphar.2020.173340
Keywords
Glycogen synthase kinase-3; Sepsis; COB-187; Cytokine; NF-kappa B
Categories
Funding
- United States National Institutes of Health [NIH R15GM110602-01A1]
Ask authors/readers for more resources
Sepsis is a serious condition that can lead to long-term organ damage and death. At the molecular level, the hallmark of sepsis is the elevated expression of a multitude of potent cytokines, i.e. a cytokine storm. For sepsis involving gram-negative bacteria, macrophages recognize lipopolysaccharide (LPS) shed from the bacteria, activating Toll-like-receptor 4 (TLR4), and triggering a cytokine storm. Glycogen synthase kinase-3 (GSK-3) is a highly active kinase that has been implicated in LPS-induced cytokine production. Thus, compounds that inhibit GSK-3 could be potential therapeutics for sepsis. Our group has recently described a novel and highly selective inhibitor of GSK-3 termed COB-187. In the present study, using THP-1 macrophages, we evaluated the ability of COB-187 to attenuate LPS-induced cytokine production. We found that COB-187 significantly reduced, at the protein and mRNA levels, cytokines induced by LPS (e.g. IL-6, TNF-alpha, IL-1 beta, CXCL10, and IFN-beta). Further, the data suggest that the inhibition could be due, at least in part, to COB-187 reducing NF-kappa B (p65/p50) DNA binding activity as well as reducing IRF-3 phosphorylation at Serine 396. Thus, COB-187 appears to be a potent inhibitor of the cytokine storm induced by LPS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available